Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 37Myelodysplastic Syndromes 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia 11Hematologic Neoplasms 10Lymphoma 9Hodgkin Disease 9Anemia, Refractory, with Excess of Blasts 9Myeloproliferative Disorders 8Multiple Myeloma 8Lymphoma, Non-Hodgkin 8Leukemia, Myelomonocytic, Chronic 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Leukemia, Biphenotypic, Acute 7Graft vs Host Disease 7Leukemia, Lymphocytic, Chronic, B-Cell 6Primary Myelofibrosis 5Neuroblastoma 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myeloid 4Congenital Abnormalities 4Anemia, Aplastic 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Polycythemia Vera 3Lymphoproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

ruxolitinib 3venetoclax 2fludarabine phosphate 2duvelisib 2thymoglobulin 1romidepsin 1itacitinib 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Lisaftoclax 1Depsipeptides 1Cyclosporins 1Cyclosporine 1Cladribine 1Busulfan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × Busulfan × 1 year × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡